| 前收市價 | 92.57 |
| 開市 | 93.20 |
| 買盤 | 0.00 x 900 |
| 賣出價 | 0.00 x 800 |
| 今日波幅 | 93.15 - 94.21 |
| 52 週波幅 | 92.19 - 108.78 |
| 成交量 | |
| 平均成交量 | 1,498,658 |
| 市值 | 192.419B |
| Beta 值 (5 年，每月) | 0.47 |
| 市盈率 (最近 12 個月) | 22.90 |
| 每股盈利 (最近 12 個月) | 4.10 |
| 業績公佈日 | 無 |
| 遠期股息及收益率 | 3.78 (4.08%) |
| 除息日 | 2024年3月07日 |
| 1 年預測目標價 | 113.76 |
- Reuters
US FDA mandates label updates on CAR-T cancer therapies
The U.S. Food and Drug Administration said on Thursday cancer therapies that use CAR-T technology will require changes to the so-called "boxed warning" to highlight the serious risk of T-cell blood cancer in patients who use these therapies. The health regulor has required related updates to other sections of the label such as warnings and precautions, postmarketing experience, patient counseling information and medication guide. In January, the FDA asked a host of drugmakers including Gilead Sciences, Johnson & Johnson and Novartis to add a boxed warning to their CAR-T cancer therapies, as it received reports of patients developing a type of T-cell blood cancer after being treated with them.
ZacksExploring Analyst Estimates for Novartis (NVS) Q1 Earnings, Beyond Revenue and EPS
Evaluate the expected performance of Novartis (NVS) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Motley Fool2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
These income stocks look like good options at current levels.
